These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38235129)

  • 21. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
    Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation.
    Konuma T; Ishiyama K; Igarashi A; Uchida N; Ozawa Y; Fukuda T; Ueda Y; Matsuoka KI; Mori T; Katayama Y; Onizuka M; Ichinohe T; Atsuta Y;
    Clin Cancer Res; 2020 Dec; 26(24):6483-6493. PubMed ID: 32895232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
    Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
    Front Immunol; 2020; 11():1534. PubMed ID: 32849519
    [No Abstract]   [Full Text] [Related]  

  • 27. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Reddy V; Winer AG; Eksioglu E; Meier-Kriesche HU; Schold JD; Wingard JR
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):1014-21. PubMed ID: 16338624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal IgA-positive plasma cells are highly sensitive indicators of alloreaction early after allogeneic transplantation and associate with both graft-versus-host disease and relapse-related mortality.
    Scheidler L; Hippe K; Ghimire S; Weber D; Weber M; Meedt E; Hoffmann P; Lehn P; Burkhardt R; Mamilos A; Edinger M; Wolff D; Poeck H; Evert M; Gessner A; Herr W; Holler E
    Haematologica; 2023 Nov; 108(11):2993-3000. PubMed ID: 37259539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
    Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
    Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
    Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
    Vander Lugt MT; Braun TM; Hanash S; Ritz J; Ho VT; Antin JH; Zhang Q; Wong CH; Wang H; Chin A; Gomez A; Harris AC; Levine JE; Choi SW; Couriel D; Reddy P; Ferrara JL; Paczesny S
    N Engl J Med; 2013 Aug; 369(6):529-39. PubMed ID: 23924003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
    Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
    PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
    Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
    Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme.
    Wang L; Kong P; Zhang C; Gao L; Zhu L; Liu J; Gao S; Chen T; Liu H; Yao H; Liu Y; Feng Y; Zhao L; Li Y; Gao L; Zhang X
    Ann Hematol; 2023 Jun; 102(6):1569-1579. PubMed ID: 37097455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
    Yuan J; Pei R; Su W; Cao J; Lu Y
    Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies: A Single-center Study].
    Lu JP; Wen SP; Wang FX; Li SH; Niu ZY; Wang Y; Zhou ZW; Xu Z; Wang ZZ; Zhang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1238-1243. PubMed ID: 35981391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.